ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,052 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 526-550 of 1,000 matching filings.

Per page
25
Current page
22
25-NSE File 001-11960

25-NSE filing

Filing date
09 Jun 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU EFFICACY RESULTS IN HER2-LOW BREAST CANCER

Filing date
06 Jun 2022
Reporting date
06 Jun 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BLOCK LISTING INTERIM REVIEW

Filing date
01 Jun 2022
Reporting date
01 Jun 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Jun 2022
Reporting date
01 Jun 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
20 May 2022
Reporting date
20 May 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

APPOINTMENT OF JOINT CORPORATE BROKERS

Filing date
09 May 2022
Reporting date
09 May 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
06 May 2022
Reporting date
06 May 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU APPROVED IN US FOR 2L HER2+ BREAST CANCER

Filing date
05 May 2022
Reporting date
05 May 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FARXIGA HFPEF PHASE III TRIAL MET PRIMARY ENDPOINT

Filing date
05 May 2022
Reporting date
05 May 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ULTOMIRIS NMOSD PH. III TRIAL MET PRIMARY ENDPOINT

Filing date
05 May 2022
Reporting date
05 May 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI COMBO GRANTED PRIORITY REVIEW FOR BTC

Filing date
04 May 2022
Reporting date
04 May 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
03 May 2022
Reporting date
03 May 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

RESULT OF AGM

Filing date
29 Apr 2022
Reporting date
29 Apr 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA PLANS NEW R&D CENTRE IN MASSACHUSETTS

Filing date
29 Apr 2022
Reporting date
29 Apr 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FIRST QUARTER 2022 RESULTS

Filing date
29 Apr 2022
Reporting date
29 Apr 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ULTOMIRIS APPROVED IN THE US FOR ADULTS WITH GMG

Filing date
28 Apr 2022
Reporting date
28 Apr 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU GRANTED BTD FOR HER2-LOW BREAST CANCER

Filing date
27 Apr 2022
Reporting date
27 Apr 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TREMELIMUMAB US PRIORITY REVIEW FOR IMFINZI COMBO

Filing date
25 Apr 2022
Reporting date
25 Apr 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU GRANTED PRIORITY REVIEW FOR HER2M NSCLC

Filing date
19 Apr 2022
Reporting date
19 Apr 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Apr 2022
Reporting date
01 Apr 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ONDEXXYA APPROVED IN JAPAN FOR FXAI REVERSAL

Filing date
29 Mar 2022
Reporting date
29 Mar 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

EVUSHELD APPROVED IN THE EU FOR COVID-19

Filing date
28 Mar 2022
Reporting date
28 Mar 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
25 Mar 2022
Reporting date
25 Mar 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

EVUSHELD POSITIVE EU CHMP OPINION

Filing date
24 Mar 2022
Reporting date
24 Mar 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

UPDATE ON CALLA PHASE III TRIAL OF CONCURRENT USE OF IMFINZI AND CHEMORADIOTHERA

Filing date
24 Mar 2022
Reporting date
24 Mar 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .